News & Updates
Excerpt from the Press Release: BOSTON, April 29, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 3 MORNINGSKY trial, a global multicenter trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial, which…
Read More
Excerpt from the Press Release: MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer, today announced updated results from its Phase 1/2 pilot trial of GC4419,…
Read More
Excerpt from the Press Release: MENLO PARK, Calif., April 29, 2021 /PRNewswire/ — LIPAC Oncology LLC today announced the conclusion of a successful Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss Phase 2b/3 clinical trials of LiPax in patients with low-grade highly recurrent non-muscle invasive bladder cancer (NMIBC). The feedback from the FDA provides…
Read More
Excerpt from the Press Release: MONMOUTH JUNCTION, N.J., April 29, 2021 (GLOBE NEWSWIRE) — Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today three key additions to its Board of Directors: Dr. David Zaccardelli, Ms. Natalie McDonald, and Mr. Gary Sender. The company also announced the transition of Robert…
Read More
Excerpt from the Article: Identifying these easily missed breaks can save patients from future negative complications or loss of function. A significant number of the most common type of wrist fracture go undetected on X-ray images, setting patients up for potential problems downstream. But, a new artificial intelligence (AI)-based automated system can improve detection rates.…
Read More
Excerpt from the Article: Moderna, one of three companies to have a COVID-19 vaccine authorized in the U.S., isn’t resting on its accomplishments but is instead working to scale up production further and improve on its vaccine. One of the downsides of the vaccine initially was its cold-storage requirements. It is approved for storage at between 36…
Read More
Excerpt from the Press Release: PHILADELPHIA, April 20, 2021 /PRNewswire/ — A trans-Atlantic collaborative group of researchers led by Children’s Hospital of Philadelphia (CHOP) has received approximately $680,000 from a group of research charities led by Solving Kids’ Cancer UK to study slowly progressive, or “indolent,” neuroblastoma, which does not respond to chemotherapy and lacks other treatment options. The grant will fund…
Read More
Excerpt from the Press Release: EMERYVILLE, Calif., April 21, 2021 /PRNewswire/ — DYNAVAX TECHNOLOGIES CORPORATION (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced Valneva SE has initiated a pivotal Phase 3 clinical trial for its inactivated, COVID-19 vaccine candidate, VLA2001, using Dynavax’s CpG 1018 adjuvant. The Phase 3 trial “Cov-Compare”, (VLA2001-301), will compare Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against…
Read More
Clinical Trials Ontario has released a Clinical Trial Restart Toolkit! “This toolkit provides a collection of best practices, considerations, and resources for clinical trial conduct in the face of the COVID-19 pandemic. The aim of this toolkit is to provide guidance for sites and sponsors that are looking to restart clinical trials during a pandemic.…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today presented full clinical data from the Phase 1b clinical trial cohort evaluating EDP1815 for the treatment of mild and moderate atopic dermatitis in a…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?